If you can't read please download the document
Upload
amberly-griffith
View
225
Download
0
Embed Size (px)
DESCRIPTION
3 CML. Historical vs. Modern Perspective ParameterHistoricalModern CourseFatalIndolent PrognosisPoorExcellent 7-yr survival40%90% Frontline Rx Allogeneic SCT; IFN- Imatinib Second line Rx? New Tyrosine Kinase Inhibitors; allo SCT